GlassScriptPhysician profile
Ashlea V Brewer
NPI 1548747462
$7,345.93
in general payments reported to CMS, 2019-2025
19 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $917 · 2022: $19.58 · 2023: $1,415 · 2024: $2,200 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,409.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,599.87 | 2021-2025 | Caplyta |
| Abbvie INC. | $833.53 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $804.33 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $757.05 | 2023-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $590.81 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $501.83 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $476.62 | 2023-2025 | Azstarys |
| Lundbeck LLC | $325.61 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $325.54 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $324.02 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $194.89 | 2024 | |
| Sunovion Pharmaceuticals INC. | $154.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $148.72 | 2023-2025 | Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $136.99 | 2025 | Jornay Pm |
| Neuronetics, INC. | $94.40 | 2021-2024 | Neurostar Tms Therapy System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.21 | 2021 | |
| Noven Therapeutics, LLC | $13.93 | 2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
| Janssen Biotech, INC. | $11.59 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlea Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.